News

Successful deployment of Arsenal's investigational first-in-class, embolic biomaterial for neurovascular conditions

First-in-class, solvent-free biomaterial achieves occlusion of small blood vessels with minimal inflammation

For the next few months, King and his colleagues are reaching out to the community to share information about the clinical trial. “Part of this process is establishing a dialogue with the community and vetting what we think we have already figured out,” King says.